Suresh Mahabhashyam
Direttore Tecnico/Scientifico/R&S presso CORVUS PHARMACEUTICALS, INC.
Provenienza dei contatti di primo grado di Suresh Mahabhashyam
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 50 | |
| Public Company | Pharmaceuticals: Major | 17 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Suresh Mahabhashyam tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| ABEONA THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
| PHARMACYCLICS, INC. | Pharmaceuticals: Major | Founder Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| SAREPTA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| ICON PUBLIC LIMITED COMPANY | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Corporate Officer/Principal | |
| GUARDANT HEALTH, INC. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Graduate Degree Undergraduate Degree | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| MIRATI THERAPEUTICS | Biotechnology | Director/Board Member General Counsel | |
| University of London | College/University | Doctorate Degree Graduate Degree | |
| Indiana University | College/University | Doctorate Degree Doctorate Degree | |
| Yale University | College/University | Corporate Officer/Principal Doctorate Degree Undergraduate Degree | |
| Princeton University | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| University of Wisconsin | College/University | Undergraduate Degree Undergraduate Degree | |
| INSEAD | College/University | Undergraduate Degree Masters Business Admin | |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Human Resources Officer Corporate Officer/Principal | |
| PDL BIOPHARMA, INC. | Biotechnology | Director/Board Member Chairman | |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Medical/Nursing Services | Corporate Officer/Principal Corporate Officer/Principal | |
American Society of Hematology
 American Society of Hematology Miscellaneous Commercial ServicesCommercial Services American Society of Hematology provides the most current practice tools, clinical support and educational products needed in hematology. The firm offers educational products and services for clinicians and scientists. The company is headquartered in Washington, DC. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor Private Equity Investor | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| UCLA Anderson School of Management | College/University | Masters Business Admin Masters Business Admin | |
| Yale School of Medicine | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Pharmaceuticals: Major | Director of Finance/CFO Comptroller/Controller/Auditor | |
| ARVINAS, INC. | Biotechnology | Director/Board Member Human Resources Officer General Counsel | |
Outpost Medicine, Inc.
 Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CHEMOMAB THERAPEUTICS LTD. | Biotechnology | Chairman Director/Board Member | |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Corporate Officer/Principal | |
| SPRINGWORKS THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Executive Officer | |
| PASSAGE BIO, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
| ALLOVIR, INC. | Biotechnology | General Counsel Chief Tech/Sci/R&D Officer | |
SpringWorks Therapeutics LLC
 SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | Biotechnology | Director/Board Member Chief Executive Officer | |
| OLEMA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman General Counsel | |
| RALLYBIO CORPORATION | Biotechnology | Founder Chief Tech/Sci/R&D Officer | |
| ARS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| EDGEWISE THERAPEUTICS, INC. | Biotechnology | Founder Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Stati Uniti | 41 |
| Regno Unito | 3 |
| Israele | 3 |
| Irlanda | 2 |
| Francia | 2 |
Settori
| Health Technology | 35 |
| Consumer Services | 10 |
| Commercial Services | 4 |
| Health Services | 3 |
| Finance | 2 |
Posizioni
| Director/Board Member | 291 |
| Corporate Officer/Principal | 181 |
| Independent Dir/Board Member | 116 |
| Undergraduate Degree | 55 |
| Chairman | 53 |
Contatti più connessi
| Insiders | |
|---|---|
| Stephen P. Squinto | 40 |
| Peter Thompson | 39 |
| Ian Clark | 35 |
| Martin MacKay | 28 |
| Max E. Link | 28 |
| Terry Gould | 26 |
| Peter Moldt | 25 |
| Christopher Coughlin | 23 |
| M. Burns | 23 |
| Linda Grais | 20 |
| David Brennan | 19 |
| Warren W. Wasiewski | 19 |
| Claude Nicaise | 16 |
| Scott Morrison | 16 |
| Julie O'Neill | 16 |
- Borsa valori
- Insiders
- Suresh Mahabhashyam
- Connessioni Società
